SOURCE: IDenta Corp.

April 18, 2008 09:30 ET

International Drug and Explosive Detection Firm IDenta Corp. Announces Plan to Re-Purchase Stock

JERUSALEM--(Marketwire - April 18, 2008) - The Board of Directors of IDenta Corp. (PINKSHEETS: IDTA) announced today that it as approved a program to re-purchase and retire outstanding shares of the company's common stock to the treasury.

A prepared statement issued by the company read: "The Board of IDenta Corp., based on our perception of the current market valuation of our company, has voted to a plan to re-purchase shares of IDTA common stock in the open market. Funding for the initial phase of the program has also been approved and the buy back program is effective immediately.

"IDenta is entering a new era as an internationally respected company with growing sales, new patents, a broadening, superior product line of chemical detectors and an established marketing network that is opening up new opportunities daily. We feel that it is now in the best interest of IDenta and our long-term shareholders to take this course of action to significantly reduce the public float of the company's shares.

"The board will carefully monitor and analyze the share price during the next three months in order to determine the exact number of shares that will be repurchased."

About Identa

Since 2003, IDenta Corporation has become recognized as a worldwide leader in the development of proprietary on-site drug and explosive detection kits, and soon to be chemical precursor detectors. IDenta develops, manufactures and distributes products for the both professional and civil markets that consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's entire product line may be found at www.IDenta.biz.

Disclaimer

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact Information

  • Contact:
    For Investor Relations, lobbying interests or information concerning
    IDenta's products internationally, contact:
    Yaacov Shoham
    IDenta Corp.
    CEO
    Tel: +972-52-6554487
    fpi@drugsdetector.com

    For Investor Relations in the US, contact:
    Randy Jacobs
    Corporate Spokesman
    IDentaNews@sitcomllc.com
    1-800-316-9437

    For information about the Accutest® -- IDenta products in the US, please
    contact:
    Mr. Eyal Golan
    COO
    JANT PHARMACAL CORPORATION
    16255 Ventura Blvd. #505
    Encino, CA 91436
    Toll Free: 800-676-5565
    http://www.accutest.net